Custom Anti-GD3 Antibody Service for Melanoma & Neuroectodermal Tumor Research

Introduction Significance Services Highlights Products Applications Popular Services Supports

Introduction: GD3—A Prominent Tumor-Associated Ganglioside

Ganglioside GD3 is a disialoganglioside primarily expressed during neuroectodermal development and aberrantly re-expressed in several malignancies, including melanomas, gliomas, and small-cell lung carcinomas. As a member of the sialic acid–containing glycosphingolipid family, GD3 plays multifaceted roles in modulating cell signaling, adhesion, proliferation, and apoptosis. Its tumor-specific overexpression and immunogenicity make it an attractive candidate for targeted cancer immunotherapy. At Creative Biolabs, we provide a suite of custom anti-ganglioside antibody solutions that include highly customized anti-GD3 antibody development solutions that enable precise and high-affinity tools for detecting, quantifying, or modulating GD3 expression in various tumor models. Our custom antibody service integrates decades of monoclonal antibody engineering expertise with modern immunogen design, screening platforms, and advanced validation tools. If you prefer a quick start, we also provide ready-to-use anti-GD3 antibody products for you.

Fig.1 Graph illustrating the sequential steps involved in the biosynthesis pathway of gangliosides, specifically focusing on the production of GD3. (OA Literature)Fig.1 Gangliosides biosynthesis pathway steps, focusing on GD3.1

Why GD3 is a Key Target in Melanoma and Neuroectodermal Tumors

GD3 is typically absent or expressed at low levels in most adult tissues but highly enriched in tumor cells of neuroectodermal origin. This differential expression forms the molecular basis for its selection as a tumor-associated antigen.

GD3 Expression Biological Implication
High in melanomas Drives metastasis and proliferation via Src-family kinases
Present in glioblastomas Promotes invasion and resistance to apoptosis
Elevated in neuroblastomas Associated with poor prognosis and drug resistance
Low in normal adult tissues Ideal for tumor-specific targeting

Creative Biolabs' Comprehensive Custom Anti-GD3 Antibody Services

Recognizing that every research project is unique, we don't offer a one-size-fits-all solution. We provide a tailored custom antibody service, leveraging a range of state-of-the-art platforms to generate the perfect anti-GD3 antibody for your specific application. Our process is collaborative, ensuring the final product aligns perfectly with your goals.

Premier Custom Anti-GD3 Antibody Generation

Creative Biolabs offers a full suite of anti-GD3 antibody services tailored to your research needs, from antigen design to antibody characterization. We can generate monoclonal, polyclonal, and recombinant formats using species of your choice. We master multiple technologies for antibody discovery, allowing us to choose the best strategy for generating high-quality antibodies against GD3.

Key Steps Details
Antigen Design & Synthesis Glycan mimicry, GD3 conjugates, lipid-coated liposomes
Immunization & Screening Multiple species (mouse, rabbit, llama, etc.)
Monoclonal Antibody Generation Hybridoma, phage display, single B-cell cloning
Antibody Characterization & Validation ELISA, WB, FACS, IHC, IF

Fig.2 Graph illustrating the sequential steps in developing GD3-targeted therapeutic strategies, including antigen design, immunization, B-cell screening, subcloning, antibody characterization, and large-scale production. (Creative Biolabs Original)Fig.2 Custom anti-GD3 antibody development workflow.

Advanced Antibody Engineering and Optimization

Generating a lead antibody is just the beginning. Our expert team can further refine your anti-GD3 antibody to enhance its properties for in vitro and in vivo studies.

  • Antibody Humanization: If you start with a murine hybridoma, we can graft the antigen-binding regions (CDRs) onto a human antibody framework. This crucial step reduces the potential for immunogenicity in later-stage models.
  • Affinity Maturation: Using techniques like site-directed mutagenesis and screening, we can improve the binding strength of your antibody to GD3, potentially increasing its potency.
  • Isotype Switching: The function of an antibody is heavily influenced by its isotype (e.g., IgG1, IgG2, IgG4). We can easily reformat your antibody into different isotypes to enhance or diminish specific effector functions, allowing you to test which format is most effective in your models.
  • Antibody Conjugation: We can chemically link your custom GD3 antibody to various payloads, opening up a world of applications.

Highlights of Our Custom Antibody Service

  • Deep expertise in glycan immunogenicity and lipid antigen presentation
  • Advanced GD3 immunogen design
  • Species-agnostic antibody platforms (mouse, rat, rabbit, llama, etc.)
  • Regulatory-aligned documentation
  • Dedicated project managers with real-time milestone updates

Ready-to-Use Anti-GD3 Antibodies Products

To accelerate your GD3-related studies, Creative Biolabs offers a selection of high-quality, ready-to-use anti-GD3 monoclonal antibodies. Available in various formats and validated for applications including IHC, ELISA, and flow cytometry, each product is QC-tested for purity, specificity, and performance. Whether you're analyzing tumor samples or designing functional assays, our GD3 antibody portfolio is designed to deliver reproducible, publication-ready results.

Applications of Anti-GD3 Antibodies in Research

Anti-GD3 antibodies have become indispensable tools in dissecting the biology of ganglioside-expressing tumors and in the development of novel cancer immunotherapy strategies. Their high specificity and adaptability to various formats make them suitable for both mechanistic studies and translational research pipelines.

Fig.3 A diagram showing different therapeutic strategies that target GD3 or GD3 synthase. The illustration categorizes various approaches (such as monoclonal antibodies, CAR-T cells, or small molecule inhibitors) and indicates their development stage, distinguishing between preclinical and clinical settings. (OA Literature)Fig.3 Overview of therapeutic strategies targeting GD3 and GD3 synthase.1

GD3 Antibody in Tumor Cell Profiling

Anti-GD3 antibodies are widely used to identify and quantify GD3-positive tumor cells in neuroectodermal malignancies such as melanoma and glioblastoma. These antibodies enable immunohistochemistry and flow cytometry-based stratification of tumor subpopulations, aiding in disease classification and biomarker validation.

Studying Immune Evasion via GD3 Antibody Tools

Anti-GD3 monoclonal antibodies are employed to investigate immune evasion mechanisms, particularly GD3-mediated suppression of natural killer (NK) and cytotoxic T cell activity. Through in vitro co-culture and cytotoxicity assays, researchers can explore how GD3 expression modulates immune checkpoint interactions and contributes to tumor immune resistance.

Enriching GD3+ Cancer Stem Cell Populations

As cancer stem cell markers, GD3-specific antibodies help enrich and track GD3-positive subpopulations associated with self-renewal and therapy resistance. This is particularly valuable in gliomas and melanomas, where GD3+ cells often exhibit more aggressive phenotypes and poor prognosis.

Anti-GD3 ADCs for Targeted Payload Delivery

For payload delivery research, anti-GD3 antibodies are utilized in the development of antibody-drug conjugates (ADCs). These engineered molecules combine target specificity with cytotoxic agents, enabling the selective killing of GD3-positive tumor cells while minimizing off-target effects.

Bispecific Antibodies Targeting GD3 and Immune Effectors

Bispecific antibody engineering involving GD3—such as CD3/GD3 or GD2/B7-H3 targeting constructs—offers a strategy to improve tumor selectivity and enhance T cell-mediated cytotoxicity. These formats bridge tumor cells with effector immune cells, enabling dual-targeting mechanisms for increased efficacy.

Humanized and Chimeric Anti-GD3 Monoclonal Antibodies

Humanized or chimeric anti-GD3 monoclonal antibodies are increasingly used in research to reduce immunogenicity and maintain effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These formats are ideal for preclinical in vivo studies and immune cell engagement assays.

GD3-Targeted CAR-T Cell Research

GD3-targeted CAR-T cell therapies represent a frontier in cellular immunotherapy research. By incorporating anti-GD3 single-chain variable fragments (scFvs) into CAR constructs, researchers can evaluate GD3-specific T cell activation, tumor infiltration, and sustained anti-tumor response in both in vitro and xenograft models.

Advancing Cancer Immunotherapy with Anti-GD3 Antibodies

Together, these applications illustrate the versatility of anti-GD3 antibodies in fundamental tumor biology research and their pivotal role in advancing targeted strategies for melanoma and neuroectodermal tumor models.

Popular Services You Might Need

Service Description
Anti-Glycolipid Antibody Service Custom development against sulfatide, galactocerebroside, globosides
Anti-Ganglioside Antibody Development Broader panel of ganglioside targets including GM1, GM2, GD1a, and GD3
Glycoarray Profiling Services Confirm antibody specificity across glycan libraries
Antibody Humanization & Optimization Affinity maturation, Fc region engineering, isotype switching. Request for details

Creative Biolabs is your trusted partner in generating fully customized anti-GD3 antibodies tailored for cancer immunotherapy and tumor biology research. Whether you're dissecting tumor-immune interactions, evaluating ganglioside dynamics, or building targeted delivery systems, our custom antibody service delivers the tools you need—with precision, speed, and scientific rigor. Ready to accelerate your GD3 antibody research? Reach out today to discuss your project specifications. Let our antibody engineering experts help you build the next breakthrough in ganglioside-targeted cancer immunotherapy.

Reference:

  1. Hein, Victoria, et al. "GD3 ganglioside is a promising therapeutic target for glioma patients." Neuro-Oncology Advances 6.1 (2024): vdae038. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1093/noajnl/vdae038

Supports

For Research Use Only. Not For Clinical Use.
Services
Anti-Glycan Antibody Development Services Anti-Glycan Antibody Engineering Services Anti-Glycan Antibody Detection Services
Support
Carbohydrate Antigens Glycans in Disease
Products
Monoclonal Antibody Polyclonal Antibody
Applications
Anti-Glycan Antibodies in Glycan Identification Anti-Glycan Antibodies in Glycan Purification Anti-Glycan Antibodies in Characterizing Cell-Surface Glycoconjugates
Platforms
Online Inquiry

Subscribe
Copyright © 2025 Creative Biolabs. All Rights Reserved.